Leadership Team
You are here:
Plasmaseq
Dr. Edwin W. Naylor is a distinguished leader in newborn screening and genetics, best known for his pioneering work in multiplexed newborn screening and the use of tandem mass spectrometry (MS/MS) for detecting metabolic disorders. He received the Robert Guthrie Award in 2014 for his contributions to the field. His pioneering work has expanded the field of genetics in allowing deep genotyping from minimal sample input.
As a pioneer in newborn screening, Dr. Naylor developed MS/MS techniques that have screened over 3 million newborns. He remains active in the field, serving as President of BioChem Genetics LLC and an adjunct professor at the Medical University of South Carolina. He also has authored over 120 publications.
Shailesh, a seasoned professional with decades of experience in forging strategic partnerships and solving customer problems thereby driving growth. With a keen eye for identifying market gaps and growth opportunities, Sam has consistently delivered results in various industrial settings. His leadership and innovative approach make him a valuable asset in driving market expansion and maximizing potential ensuring growth for clients as well.
Dr. Samur, a distinguished PhD scientist in medical informatics, is at the forefront of groundbreaking research in Myeloma working on translational computational biology to understand development and progression of Myeloma and other cancers. With a wealth of expertise in leveraging advanced computational techniques, Dr. Samur delves into the intricate landscape of cancer genetics, seeking to unravel the complexities of tumor biology and identify novel therapeutic targets. Dr. Samur is driving forward the integration of informatics and medical research, paving the way for more effective treatments and personalized medicine approaches in the fight against cancer.
Dr. Hervé Avet-Loiseau is the head of IFM (Intergroupe Francophone Myélome) and head of the Myeloma Genomics Lab at University Hospital in Toulouse. Dr. Hervé Avet-Loiseau is a prominent figure in the field of oncology, particularly renowned for his groundbreaking contributions to the understanding and treatment of multiple myeloma, a complex and often challenging cancer of the plasma cells. As a distinguished hematologist and researcher, Dr. Avet-Loiseau’s career spans several decades and is marked by numerous achievements and advancements in the realm of cancer genetics.
Dr. Parth Shah is a distinguished physician and researcher specializing in precision health, artificial intelligence, and genome informatics. He currently serves as the Associate Clinical Director at the Dartmouth Center for Precision Health and Artificial Intelligence (CPHAI) and as the Director of Genome Informatics at Dartmouth Hitchcock. Dr. Shah works to bridge the fields of medicine, genomics, and cutting-edge technology, focusing on integrating genomic data with artificial intelligence to advance personalized healthcare. His leadership at CPHAI positions him at the forefront of efforts to harness the power of AI in precision medicine, aiming to improve outcomes through tailored treatments and predictive analytics.
With a strong foundation in both clinical medicine and computational biology, Dr. Shah is dedicated to advancing the application of genomics and AI in healthcare, aiming to improve patient care and enable more precise, data-driven medical interventions.